Clinical trial
A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer
NCT02536794 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer
- Lead sponsor
- Northwestern University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 14, 2016
- Completion date
- January 22, 2021
- Enrollment
- 30 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
estrogen receptor negative, estrogen receptor positive, her2/neu negative, recurrent breast carcinoma, stage iv breast cancer